Skip to main content

Table 2 Baseline characteristics of the study population

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Demographics Total
(n = 135)
FMS/RSV
(n = 46)
FMS
(n = 45)
RSV
(n = 44)
P-value
Age (year) 60.5 (8.7) 59.3 (8.7) 62.3 (9.5) 59.9 (7.7) 0.137a
Sex, men, n (%) 99 (73.3) 31 (67.4) 34 (75.6) 34 (77.3) 0.524b
Body mass index (kg/m2) 25.6 (2.7) 26.4 (2.8) 25.1 (2.6) 25.4 (2.8) 0.033a
Baseline blood pressure, mmHg      
 Systolic 152.8 (9.5) 152.5 (9.9) 151.3 (9.0) 154.7 (9.5) 0.157a
 Diastolic 89.4 (9.1) 89.4 (8.3) 85.8 (9.3) 93.1 (8.5) 0.001a
Baseline Pulse Rate (beats/min) 75.2 (12.1) 76.4 (13.1) 73.0 (10.9) 76.2 (12.3) 0.441a
Baseline LDL-C (mg/dL) 165.7 (34.6) 171.3 (36.0) 164.1 (39.6) 161.4 (26.7) 0.294a
Smoking, n (%)      
 Current Smoker 37 (27.4) 14 (30.4) 12 (26.7) 11 (25.0) 0.933b
 Non-smoker 57 (42.2) 17 (37.0) 2 0 (44.4) 20 (45.5)  
 Ex-smoker 41 (30.4) 15 (32.6) 13 (28.9) 13 (29.6)  
Drinking, n (%)      
 Current drinker 83 (61.5) 30 (65.2) 27 (60.0) 26 (59.1) 0.811b
 Non-drinker 52 (38.5) 16 (34.8) 18 (40.0) 18 (40.9)  
Medication history of cardiovascular system, n (%)      
 Lipid modifying agents 93 (68.9) 31 (67.4) 34 (75.6) 28 (63.6)  
 ACE inhibitors or ARBs 81 (60.0) 28 (60.9) 29 (64.4) 24 (54.6)  
 Calcium channel blockers 38 (28.2) 9 (19.6) 13 (28.9) 16 (36.4)  
 Beta blockers 10 (7.4) 1 (2.2) 4 (8.9) 5 (11.4)  
 Cardiac drugs 7 (5.2) - 5 (11.1) 2 (4.6)  
 Diuretics 5 (3.7) 1 (2.2) 2 (4.4) 2 (4.6)  
 Peripheral vasodilators 4 (3.0) 1 (2.2) 3 (6.7) -  
 Vasoprotectives 1 (0.7) - - 1 (2.3)  
Medical history, n (%)      
 Diabetes mellitus 33 (24.4) 8 (17.4) 16 (35.6) 9 (20.5)  
 Angina pectoris 6 (4.4) 1 (2.2) 2 (4.4) 3 (6.8)  
  1. Data are expressed as mean and standard deviation in parenthesis, and number and percent in parenthesis
  2. FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LDL-C low-density lipoprotein cholesterol
  3. Difference among treatment groups: aKruskal-Wallis test for continuous variables, bchi-square test for categorical variables